Press "Enter" to skip to content

Pfizer/BioNTech Seek First Vaccine Approval in US

Shares

Key Points

  • US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towards relief as surging infections prompt a return to shutdowns that traumatized nations and the global economy earlier this year.
  • The US Food and Drug Administration (FDA) said its vaccines committee would meet on December 10 to discuss the request for emergency use authorization.
  • The BioNTech/Pfizer shot and another one being developed by the US firm Moderna have taken the lead in the global chase for a vaccine.
  • Visit The Financial Today’s homepage for more stories.

WASHINGTON — US biotech giant Pfizer and German partner BioNTech sought approval Friday to roll out their coronavirus vaccine early, a first step towards relief as surging infections prompt a return to shutdowns that traumatized nations and the global economy earlier this year.

The world is looking to scientists for salvation from the global pandemic, as a new wave of infections forces New York to shut schools and California to implement night-time curfews.

The US Food and Drug Administration (FDA) said its vaccines committee would meet on December 10 to discuss the request for emergency use authorization.

“The FDA recognizes that transparency and dialogue are critical for the public to have confidence in COVID-19 vaccines,” the organization’s head Stephen Hahn said in a statement.

“I want to assure the American people that the FDA’s process and evaluation of the data for a potential COVID-19 vaccine will be as open and transparent as possible.” 

He said he could not predict how long the review would take, but the federal government said earlier the final green light would probably come in December.

Get unlimited access to TFT Premium content for FREE!

Join 23,000+ subscribers and enjoy free access to TFT premium news & stories!

Be First to Comment

Leave a Reply